Podcasts about wegovy

Worried about gaining weight back after Ozempic, Wegovy, Mounjaro, or Zepbound?You're not alone. One of the biggest concerns people have during their GLP-1 journey is what happens after the weight loss phase—and how to actually maintain their results long-term.In this episode, Registered Dietitian and GLP-1 expert Gianna breaks down what sustainable weight maintenance really looks like, why maintaining weight loss is different from losing weight, and the habits that support long-term success.Because keeping weight off isn't about being perfect. It's about building routines that you can realistically maintain for years to come.We're covering:Why weight maintenance is different than weight lossCommon reasons people regain weight after losing itThe role of appetite, food noise, and long-term behavior changeWhy protein and strength training matter for maintenanceHow muscle supports long-term health and weight managementThe mindset shifts that make maintenance easierWhy all-or-nothing thinking keeps people stuckWhat successful long-term maintenance actually looks likeWhether you're currently taking Ozempic, Wegovy, Mounjaro, or Zepbound—or simply thinking ahead to the future—this episode will help you focus on the habits that support lasting results.

Can retatrutide finally be the breakthrough obesity treatment we've been waiting for? The answer is yes—and the data is stunning. In this episode I'm walking you through the biggest obesity medicine discovery from the ADA's 86th Scientific Session: retatrutide, a triple hormone receptor agonist showing weight loss results that rival bariatric surgery. You'll learn what makes retatrutide different from Wegovy and Zepbound, the stunning results from the Triumph 1 trial, what the side effects actually look like, and when this medication will finally be available. Weight loss medications are evolving faster than ever. But what you really need to know is what these results mean for your health. Listen now! Episode Highlights: Retatrutide is a triple hormone agonist that targets GLP-1, GIP, and glucagon receptors Participants lost an average of 28.3% of their body weight in 80 weeks Two-thirds of participants achieved a normal BMI—moved from obese to healthy weight Nearly everyone with prediabetes reversed it and returned to normal blood sugar Over 70% reduction in knee osteoarthritis pain and 60% reduction in sleep apnea severity The highest discontinuation rate due to side effects was only 11%—mainly GI issues Retatrutide is not yet FDA approved but anticipated to launch early 2027 Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

durée : 00:00:54 - C'est une nouveauté dans la prise en charge de l'obésité. Deux médicaments, le Wegovy et le Mounjaro, sont pris en charge par l'Assurance-maladie à partir de lundi. - réalisation : Service sciences, santé, environnement et technologie Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

It's Episode 20 of Season 24. Come celebrate the 15th Anniversary of The NoSleep Podcast!"Listen Closely" by Chris Hicks (Story starts around 00:08:40)Produced by Jeff ClementCast: Brie - Sarah Ruth Thomas, Janelle - Yenni Ann, Colonel Wayne - Peter Lewis, Automated Voice - Erin Lillis"Hole(d)" by Garrett Atkinson (Story starts around 00:25:45)TRIGGER WARNING!Produced by Claudius MooreCast: Colin - Atticus Jackson, Doug - Dan Zappulla, Heather - Rima Mycynek, Customer - David Cummings, Voice #1 - Jeff Clement, Voice #2 - Nichole Goodnight"New Admission, Room Six" by Arlo Vell (Story starts around 00:54:50)Produced by Phil MichalskiCast: Dr. Richard - Graham Rowat, Beatrice - Erin Lillis, Molly - Mary Murphy, Richie - Kyle Akers"Return to Shiver Creek" by Zalina Alvi (Story starts around 01:24:20)Produced by Jesse CornettCast: Maddy - Nikolle Doolin, Sarah - Wafiyyah White, Dan - Elie Hirschman"Marnie and Kyle in the Quick 'n' Now" by Jason Washer (Story starts around 02:01:50)TRIGGER WARNING!Produced by Phil MichalskiCast: Marnie - Linsay Rousseau, Kyle - Matthew Bradford, Jaime - Jesse CornettThis episode is sponsored by:Mint Mobile - Ditch overpriced wireless with Mint Mobileís deal and get premium wireless service for 15 bucks a month. Cut your wireless bill to 15 bucks a month at mintmobile.com/nosleepWeight Loss by Hims - Ready to reach your weight loss goals? Weight Loss by Hims and WegovyÆ. Get a personalized, affordable plan that gets you. Go to Hims.com/nosleep.Mars Men - With Mars Men, your natural ability to forge usable testosterone is optimized. Mars Men supports healthy T levels, energy, and stamina. Get 50% off for life plus free shipping and 3 free gifts at MenGoToMars.comClick here to learn more about The NoSleep Podcast teamClick here to learn more about Yenni Ann and the Story Sirens PodcastCheck out our NEW MERCH!Click here to learn more about the Crimewave at Sea 2.0 Cruise!Click here to get your Crimewave at Sea discount code and bonus event!Click here to learn more about Zalina AlviClick here to learn more about Jason Washer Executive Producer & Host: David CummingsMusical score composed by: Brandon Boone15th Anniversary illustration courtesy of Catriel TallaricoThe NoSleep Podcast is Human-made for Human Minds. No generative AI is used in any aspect of work.Audio program ©2026 - Creative Reason Media - The copyrights for each story are held by the respective authors. No duplication or reproduction of this audio program is permitted without the written consent of Creative Reason Media. No part of this audio program may be used or reproduced in any manner for the purpose of training artificial intelligence technologies or systems. All rights reserved.

GLP-1 drugs were first approved to treat diabetes and then caused a frenzy when it was discovered they were great for weight loss. But now scientists are discovering the drugs that have brand names including Ozempic and Mounjaro might offer so much more, from reducing the risk of heart attack to treating kidney disease. Today, Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University on how Ozempic is shaking things up, again. Featured:  Doctor Paul Joyce, a pharmaceutical scientist at Adelaide University 

Welcome back to our weekend Cabral HouseCall shows!   This is where we answer our community's wellness, weight loss, and anti-aging questions to help people get back on track!   Check out today's questions:    Lisa: Hello Dr. Cabral, my 4 year old has Molluscum Contagiosum, I found an old podcast from 2017, episode 681, and wanted to know if you have any new updated information. They are mostly on her right side of her extremities. She had one for a while that would not heal for months. It was constantly red, inflammed and bleeding. I applied the recommended ACV and by the next day it was so much better. After about a week, its was gone. She still has the little "white head" pimples on her arm and leg. The protocol that was recommended then was for an 11 yr old and wanted to know if you suggest anything for her or have any new updated information. She does take a daily multi and a immune support that has echinacea and elderberry. Thank you for all your help in trying to keep the community healthy.        Bettina: Hello, Your knowledge has inspired me, thank you very much. I know someone who lost 25–30 kg with Wegovy and now feels and look great despite eating ultra-processed foods, drinking Pepsi Max and occasional energy drinks. I try to follow your health principles—daily smoothie with DNS, whole foods, supplements, and mainly water. Still, I've been diagnosed with lipedema (stage 1–2), have fluid retention in my legs, excess weight, and daily pain (knees, heel spur, and foot pain). At times, I feel tempted to try Wegovy and care less, as I seem to struggle more while having limited time and money for treatments and supplements. Why is there such a difference between people, and where should I start?       Sonny: Hi Dr. Cabral, thank you for all your help and education over the years. My name is Sonny, I'm an IHP Level 2 practitioner from the UK writing on behalf of my 68-year-old mum. For several years she has experienced chronic coughing whenever eating solid meals, but not with liquids or smoothies. She also gets reflux and coughing when lying flat at night or during Pilates exercises. From an IHP2 lens I suspected low stomach acid, so we trialled ACV before meals along with digestive enzymes and HCL + pepsin. For the first time in years she ate without coughing, which felt like a major breakthrough. However, lying flat still triggers symptoms, making me wonder about LPR or a hiatal hernia alongside hypochlorhydria. What would you suggest next please?       Tricia: Hi Dr. Cabral -- my question is about your advance collagen support. Is it hydrolyzed? I have a lot of issues with my tendons and do get hip bursitis. I also take a good day or two to recover when I do exercise. I can do back to back days and trust me I'm not lifting heavy anymore now that I'm in my 50's. I have spine issues as well. Would your collagen support be good for my tendons or it mostly for hair, skin and nails? It seems that I stay in PT and do exercise but I can't seem to get my muscle imbalances under control especially as I age. Always love your advice. You are amazing! Thank you!      Tricia: Hi - yes me again. This question is for my 65 year old sister. She was recently under a lot of stress at home with her child leaving the country to live and her husband diagnosed with cancer. The stress was hard on her. Now pills are getting stuck in her esophagus. She went to the dr and they did all the tests & procedures. All was ok. They did stretch her esophagus a bit. We believe she is in the early stage of acid reflux. We want to heal it before it gets worse. I told her to absolutely not take the purple pill! What would you recommend? She can't afford the tests right now (due to hubby) and since she can't swallow pills easily she is at a loss. Do you have any advice or guidance for someone who can't take pills? Can she do CBO Pro and open up pills? Help       Thank you for tuning into today's Cabral HouseCall and be sure to check back tomorrow where we answer more of our community's questions!    - - - Show Notes and Resources: StephenCabral.com/3781 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Morse code transcription: vvv vvv Jilted Swansea bride Kayley Stead who still held wedding gets engaged England midfielder Declan Rice on his sunburn and World Cup heat Child rape sentence reignites scrutiny of UK high street mini marts Weight loss drug Wegovy to be available in pill form in UK for first time El Ni o has begun, scientists say, and could bring record heat Mis Teeq on reuniting, UK garage and Alesha Dixons ad libs Mean Girls Lead actress scared after disorder as Belfast shows cancelled Hidden house farmer hits back after conviction Cramlington crash police officer, 19, dies in hospital Brother and sister guilty of attacking teenage girls in Dundee

Morse code transcription: vvv vvv Mis Teeq on reuniting, UK garage and Alesha Dixons ad libs Hidden house farmer hits back after conviction Mean Girls Lead actress scared after disorder as Belfast shows cancelled England midfielder Declan Rice on his sunburn and World Cup heat Jilted Swansea bride Kayley Stead who still held wedding gets engaged Cramlington crash police officer, 19, dies in hospital Brother and sister guilty of attacking teenage girls in Dundee Child rape sentence reignites scrutiny of UK high street mini marts El Ni o has begun, scientists say, and could bring record heat Weight loss drug Wegovy to be available in pill form in UK for first time

Morse code transcription: vvv vvv Mean Girls Lead actress scared after disorder as Belfast shows cancelled Jilted Swansea bride Kayley Stead who still held wedding gets engaged Brother and sister guilty of attacking teenage girls in Dundee Child rape sentence reignites scrutiny of UK high street mini marts El Ni o has begun, scientists say, and could bring record heat Weight loss drug Wegovy to be available in pill form in UK for first time England midfielder Declan Rice on his sunburn and World Cup heat Mis Teeq on reuniting, UK garage and Alesha Dixons ad libs Cramlington crash police officer, 19, dies in hospital Hidden house farmer hits back after conviction

Morse code transcription: vvv vvv Jilted Swansea bride Kayley Stead who still held wedding gets engaged Child rape sentence reignites scrutiny of UK high street mini marts Weight loss drug Wegovy to be available in pill form in UK for first time El Ni o has begun, scientists say, and could bring record heat England midfielder Declan Rice on his sunburn and World Cup heat Mis Teeq on reuniting, UK garage and Alesha Dixons ad libs Hidden house farmer hits back after conviction Brother and sister guilty of attacking teenage girls in Dundee Cramlington crash police officer, 19, dies in hospital Mean Girls Lead actress scared after disorder as Belfast shows cancelled

Semaglutide. Tirzepatide. Retatrutide. The peptide conversation has taken over every gym, group chat, and social media feed. But the part about muscle loss, osteopenia, and what the gray market is actually selling you? That part is getting buried. Chalene Johnson sits down with Adam Schafer, co-host of Mind Pump, one of the top fitness podcasts in the world with nearly half a billion downloads. Adam spent three and a half years running real test groups on GLP-1s including Ozempic and Wegovy. What he found changed his perspective entirely and he is not holding back. This conversation covers what is actually driving muscle and bone density loss in women over 40 and 50, why the scale and the mirror are lying about body composition, and what most women are getting wrong about building real strength in midlife. Plus the truth about the gray market and what those peptides may actually contain. This is the conversation the fitness industry is not having and it is one every woman over 40 needs to hear.

Amye is joined by Becca to “investigate” Steven McBee Senior. As you may remember, he pleaded guilty to fraud last year and has recently been sentenced. But what exactly did Steven McBee Senior do to land himself in jail for 24 months? We took to the internet to find out.Join us next week for our full coverage of The McBee Dynasty season 3!GET BONUS CONTENTUnlock ad-free episodes and exclusive bonus recaps by joining our community!Patreon: patreon.com/littlemissrecap (50% your first month through the month of June!Website: littlemissrecap.com/supportSUPPORT OUR SPONSORSFACTOR MEALS helps you save time in the kitchen with delicious, nutritious, chef-prepared cuisine. Meals come fully prepared and ready to eat in 2 minutes.Use our link and get 50% off your first box plus free shipping. Visit: www.factormeals.com/littlemiss50off and use code littlemiss50off.Hers now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy pill and the Wegovy pen. Visit forhers.com/LMR to get personalized, affordable care that gets you. OUR OTHER SHOWS & MERCHTrue Crime: Hear our latest documentary deep-dives on Murder She Watched at murdershewatchedpod.comShop Merch: Get your podcast gear at littlemissrecap.threadless.comCONNECT WITH USInstagram: @littlemissrecapFacebook Group: Little Miss Recap Podcast CommunityYouTube: Watch our recaps hereContact: Voicemail at littlemissrecap.com or email littlemissrecap@gmail.com Hosted on Acast. See acast.com/privacy for more information.

In part two of the GLP-1 series, Melissa gets practical. What does it actually feel like to be on this medication? What does responsible use look like day to day? And how do you get the best results at the lowest effective dose possible?Whether you just started, you're a few months in, or you're wondering why you're not seeing the results you expected — this episode is for you.IN THIS EPISODE, YOU'LL LEARN:Why you forget about food on a GLP-1 and why that feeling of relief is also where your responsibility beginsWhat the flat affect actually is, why it happens, and what it tells you about your doseWhy GLP-1 receptors live in the brain's reward center — and what that means for your dopamine, your drive, and your nervous systemThe difference between microdosing and the lowest effective dose (and why that distinction matters more than the label)FDA-approved dosing for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — and where Melissa would actually startWhy digestion has to come first before or while on this medicationThe truth about blood sugar stability on a GLP-1 and why the medication doesn't do that work for youWhy women on GLP-1 are losing muscle without realizing it — and exactly what to do about itProgressive overload: what it actually means and why going through the motions isn't enoughWhy Melissa recommends Cronometer over MyFitnessPal for tracking on a GLP-1Hair loss — medication side effect or weight loss side effect? Melissa breaks down the differenceFatigue — why it's actually both, and what to do depending on which one it isWhy perimenopause symptoms can get louder on a GLP-1 and what's happening hormonallyHow to know if you're actually at a plateau (hint: four weeks is the threshold)What to do when you're at max dose and the scale still isn't movingHow long is it okay to stay on a GLP-1 — and what the long-term concerns actually areTIMESTAMPS:00:00 — Welcome back + recap of episode one 01:45 — What it actually feels like when you first start 03:30 — The flat affect and the dopamine loop 07:50 — Strength training as a natural dopamine regulator 10:00 — The lowest effective dose and what microdosing actually means 12:00 — Semaglutide dosing overview (Wegovy, Ozempic) 13:45 — Tirzepatide dosing overview (Zepbound, Mounjaro) 15:00 — How to advocate for a lower starting dose with your provider 16:00 — Melissa's personal experience: 1 mg tirzepatide for inflammation 23:30 — Making the medication work hard for you: the foundation 25:00 — Digestion first — why gut health matters before you start 26:30 — Blood sugar stability is your responsibility 29:00 — Protein first, always 31:00 — Why women on GLP-1 are losing muscle 33:30 — Progressive overload — what it actually looks like 35:00 — Track your food — why Cronometer and why it's non-negotiable 38:30 — Side effects: medication vs. weight loss (two different categories) 39:00 — Hair loss explained 40:50 — Fatigue explained 42:00 — Nausea, constipation, gut symptoms 42:45 — Perimenopause, hormonal shifts, estrogen dominance44:30 — How to know if you're actually at a plateau 48:00 — Max dose: what to do when you're there 48:30 — How long is it okay to stay on a GLP-51:00 — Download the GLP-1 Support Guide + closeRESOURCES:Download the GLP-1 Support Guide — everything you need to use this medication responsibly: workouts with logging space, protein meal plan, nutrition framework, and tracking tools. melissaeichwellness.com/GLP1guideBook a free consultation with Melissa — whether you're considering GLP-1, already on it, or wanting gut or hormone support while on it: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=6a0cb936104f4243883a46dfGut Healing Program or Complete Hormone Program: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=69fe864f4b36932a1ec4aba4Related episodes:Episode [#179]: GLP-1 Series, Part 1 — The Shame, the Gray Area, and Weight Loss Resistance: https://podcasts.apple.com/us/podcast/179-glp-1-for-midlife-women-where-to-begin-part-1-3/id1650475536?i=1000771142749DUTCH test series — perimenopause, weight loss resistance, and estrogen detox - https://podcasts.apple.com/us/podcast/176-perimenopause-weight-gain-and-the-dutch-test/id1650475536?i=1000767363294CONNECT WITH MELISSA:Instagram: @melissa_eich Website: melissaeichwellness.com Email: melissa@melissaeichwellness.comABOUT THE SHOW:Body-Led by Design is a podcast for women who are done guessing and ready to understand what's actually happening in their bodies. Hosted by Melissa Eich, registered nurse, hormone and nervous system coach, and somatic practitioner, each episode brings the real conversations from her practice so you can walk away more informed, more empowered, and a little less alone in what you're navigating.LEAVE A REVIEW:If this episode resonated with you, a five-star review means the world. It helps more women find this podcast and get the information they actually need.SEO KEYWORDS:GLP-1 side effects, semaglutide weight loss, tirzepatide lowest effective dose, microdosing GLP-1, hair loss on Ozempic, muscle loss GLP-1, weight loss plateau GLP-1, GLP-1 fatigue, Wegovy responsible use, perimenopause GLP-1, how long to stay on GLP-1, GLP-1 support women over 40

Timestamps : 00:00 — Intro — Welcome to the Holistic Kids Show 00:20 —  The Childhood Obesity Crisis: The Numbers 01:14 — Guest Introduction: Ashley Koff, RD 02:12 — Ashley's Personal Story & What Drove Her Mission 04:34 — Rethinking Weight: It's a Signal, Not a Sentence 05:15 — Introducing Your Best Shot & Weight Health 06:07 — Understanding Hormones: GLP-1, GIP, CCK & PYY Explained Simply 08:15 — How Gut Hormones Control Blood Sugar, Appetite & Bone Health 10:16 — The Gut-Hormone Connection: Why Your Microbiome Matters 11:05 — Can Kids Take GLP-1 Hormones? 11:25 — Ozempic, Wegovy & GLP-1 Medications Explained 13:40 — GLP-1 Medications Approved for Kids 10+ — What Parents Must Know 15:28 — 3 Daily Habits to Naturally Balance Your Hormones 17:21 — Habit #2: Eat Like a Race Car — Fueling at the Right Times 18:04 — Habit #3: Move After Every Meal — Why 7 Minutes Matters 22:03 — "Better, Not Perfect" — What That Really Means for Teens 25:00 — The One Nutrition Rule Every Kid Should Know 29:49 — Where to Find Ashley Koff & Her Resources One in five US children lives with obesity — but are we asking the right questions? In this powerful episode, the Holistic Kids crew sits down with Ashley Koff, RD, USA Today bestselling author of Your Best Shot and a leading weight health practitioner with over 25 years of experience. Ashley flips the script on how we talk about weight with kids — moving away from diets, BMI, and body shame, and toward understanding what the body is actually telling us. She explains how hormones like GLP-1, GIP, and PYY are made in the gut lining, why antibiotics and medications can disrupt them for years, and what that means for growing bodies. The conversation also tackles the rising use of GLP-1 medications (like Ozempic and Wegovy) in kids as young as 10 — what the research says, what parents and teens should know, and why these medications are a tool, not a solution on their own. In this episode, you'll learn: Why weight is a signal, not a sentence What GLP-1, GIP, and gut hormones actually do — explained simply How antibiotics and medications affect your hormones for years The truth about GLP-1 medications for kids and teens 3 daily habits to naturally support hormone balance Why BMI is a flawed measure — and what to look at instead The "race car" nutrition approach that keeps your body running better What "better, not perfect" really means for teenagers Guest: Ashley Koff, RD — Founder of The Better Nutrition Program, author of Your Best Shot, recognized by CNN as one of the Top 100 Health Makers.

Could eating late at night be hurting your gut health? Are prebiotic and probiotic sodas actually good for your microbiome? And what do GLP-1 weight loss drugs such as Ozempic and Wegovy mean for digestion, constipation, and gut bacteria? Dr. Will Bulsiewicz joins Chuck Carroll on The Exam Room Podcast to answer the most Googled gut health questions from listeners.

Amye is joined by Kyla to discuss Hollywood Demons S2:EP5 Surviving 16 & PregnantExpecting teens met unexpected backlash after appearing on the controversial MTV show, "16 and Pregnant"; sixteen years since the show's debut, cast members open up about the struggles they faced in its wake, including homelessness, addiction, an FBI raid, and insinuations of murder.GET BONUS CONTENTUnlock ad-free episodes and exclusive bonus recaps by joining our community!Patreon: patreon.com/littlemissrecap (50% your first month through the month of June!Website: littlemissrecap.com/supportSUPPORT OUR SPONSORSFACTOR MEALS helps you save time in the kitchen with delicious, nutritious, chef-prepared cuisine. Meals come fully prepared and ready to eat in 2 minutes.Use our link and get 50% off your first box plus free shipping. Visit: www.factormeals.com/littlemiss50off and use code littlemiss50off.Hers now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy pill and the Wegovy pen. Visit forhers.com/LMR to get personalized, affordable care that gets you. OUR OTHER SHOWS & MERCHTrue Crime: Hear our latest documentary deep-dives on Murder She Watched at murdershewatchedpod.comShop Merch: Get your podcast gear at littlemissrecap.threadless.comCONNECT WITH USInstagram: @littlemissrecapFacebook Group: Little Miss Recap Podcast CommunityYouTube: Watch our recaps hereContact: Voicemail at littlemissrecap.com or email littlemissrecap@gmail.com Hosted on Acast. See acast.com/privacy for more information.

Καλεσμένος ο Δρ. Αριστομένης Τουρβάς, Παθολόγος–Εντατικολόγος, με πιστοποίηση SCOPE και εξειδίκευση στην παχυσαρκία.   Μια νέα εποχή φαίνεται να ξεκινά στην αντιμετώπιση της παχυσαρκίας. Σε κλινικές μελέτες ενός νέου φαρμάκου, ασθενείς έχασαν πάνω από το 25% του βάρους τους. Μέσα σε λίγα χρόνια, φάρμακα όπως το Ozempic, το Wegovy και το Mounjaro πέρασαν από τα ιατρεία και τα επιστημονικά συνέδρια, στα πρωτοσέλιδα, στα social media και στις καθημερινές συζητήσεις. Για κάποιους αποτελούν μια επανάσταση στην ιατρική. Για άλλους, μια εξέλιξη που συνοδεύεται από μεγάλες προσδοκίες αλλά και σημαντικά ερωτήματα για την ασφάλεια, τη χρήση και το μέλλον τους.   Μπορούν πραγματικά αυτά τα φάρμακα να αλλάξουν τον τρόπο με τον οποίο αντιμετωπίζουμε την παχυσαρκία; Πόσο αποτελεσματικά και πόσο ασφαλή είναι; Σε ποιους απευθύνονται; Και βρισκόμαστε πράγματι μπροστά σε μια νέα εποχή στην ιατρική; Ίσως στη σημαντικότερη εξέλιξη στην αντιμετώπιση της παχυσαρκίας από τότε που η ιατρική άρχισε να τη θεωρεί νόσο;

The Layoff Tracker, Cigna's GLP-1 Cut & What Happens When Compliance FailsJune 8th, 2026. Bo and Luke break down three stories connected by the same thread: what happens when organizations wait too long to act.

GLP-1 medications like Ozempic, Wegovy, and Zepbound have become some of the most talked-about treatments for weight loss, but their benefits may extend far beyond the scale. In this episode, Diana breaks down what GLP-1 medications are, how they work in the body, and what current research shows about kidney health. She explores the growing evidence for kidney protection, discusses emerging research in autosomal dominant polycystic kidney disease (ADPKD), and shares practical considerations for people with PKD who are considering semaglutide or tirzepatide medications. SHOW NOTES, REFERENCES, & TRANSCRIPTS www.thepkddietitian.com/58 Episode #57: Weight Loss & PKD: Can It Slow Kidney Growth and Disease Progression? GLP1 Clinical Trial: Glucagon-Like Peptide-1 Receptor Agonist in ADPKD FLOW Trial: https://pubmed.ncbi.nlm.nih.gov/38785209/ Support the Show: patreon.com/PKDDietitian WORK WITH DIANA: thepkddietitian.com/workwithme HAVE A QUESTION? Send a message to info@thepkddietitian.com FIND THE PKD DIETITIAN ONLINE Patreon: PKDDietitian Instagram: @The.PKD.Dietitian Facebook: The PKD Dietitian Website: thepkddietitian.com Support the show and access future bonus content and deeper PKD nutrition insights: patereon.com/PKDDietitian DISCLAIMER The PKD Dietitian Podcast is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.

90 Day Fiance S12:EP5 & The Last Resort S3:EP2Amye is joined by Amanda to discuss 90 Day Fiance S12:EP5 & The Last Resort S3:EP2The Last Resort starts at 48 mins. 90 Day Fiance:Something Old, Something New - Rasit offends Mallorie's ex-fling Brandon at his USA-themed welcome party. Edward learns Marissa's strict house rules and meets her ex-husband. Debby and Mido struggle to make amends. Josh isn't impressed with Catie and his new apartment. Ashia heads to Nigeria to reunite with Maxwell.Last Resort:Last Crown Standing - Shekinah and Sarper remain distant. Jenny reveals why she doesn't trust Sumit. Rebecca and Zied unravel over control. Kara and Guillermo face painful truths. Patrick and Thais disagree on how to spend their time. Pao questions her future with Russ.GET BONUS CONTENTUnlock ad-free episodes and exclusive bonus recaps by joining our community!Patreon: patreon.com/littlemissrecap (50% your first month through the month of June!Website: littlemissrecap.com/supportSUPPORT OUR SPONSORSFACTOR MEALS helps you save time in the kitchen with delicious, nutritious, chef-prepared cuisine. Meals come fully prepared and ready to eat in 2 minutes.Use our link and get 50% off your first box plus free shipping. Visit: www.factormeals.com/littlemiss50off and use code littlemiss50off.Hers now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy pill and the Wegovy pen. Visit forhers.com/LMR to get personalized, affordable care that gets you.OUR OTHER SHOWS & MERCHTrue Crime: Hear our latest documentary deep-dives on Murder She Watched at murdershewatchedpod.comShop Merch: Get your podcast gear at littlemissrecap.threadless.comCONNECT WITH USInstagram: @littlemissrecapFacebook Group: Little Miss Recap Podcast CommunityYouTube: Watch our recaps hereContact: Voicemail at littlemissrecap.com or email littlemissrecap@gmail.com Hosted on Acast. See acast.com/privacy for more information.

Linktree for Community ResourcesNeed help appealing a GLP-1 Insurance Denial? FindHonestCare.com/KimRo - Telehealth for GLP1 Weight ManagementThe Absolute Lies You've Heard About GLP-1s (Ozempic Myths Debunked) [REPLAY]Are you being lied to about Ozempic, Mounjaro, and Wegovy? In this special replay episode, leading obesity medicine specialists break down the biggest GLP-1 myths taking over your feed. We are reposting this crucial conversation because it is more relevant than ever. With GLP-1 price changes and expanding access options through federal programs like the Medicare GLP-1 Bridge, understanding the real science behind these medications is essential for patient advocacy.We are sharing a few favorite replay episodes right now while Kim is away on bereavement leave following the loss of her sister. We want to deeply thank our subscribers for staying engaged and supporting the show during this time.In this episode of The Plus Sidez Podcast, Kat joins Kim to sit down with obesity medicine specialists Dr. Matea Rentea and Dr. Ali Novitzki to help listeners better understand their disease and feel empowered in their healthcare journey.The Myths We Debunk:The Muscle Loss Scare: The data behind weight loss and body composition, explaining why the medication itself is not destroying your lean mass.The Willpower Narrative: Why obesity is a genetic, chronic metabolic disease rooted in brain biology, not a failure of personal willpower.The Shot-Only Illusion: How the medication works alongside your body's natural satiety signals and gut receptors.Obesity Doctor Guidance Shared:Metabolic Protection: A practical discussion on utilizing a 10-minute fitness routine and a 100-gram protein framework to maintain lean mass and support insulin sensitivity.System Navigation: Insights on navigating insurance barriers, managing prior authorizations, and advocating for proper medical care.Mental Resilience: Tools to process unsolicited comments about your weight and protect your peace from societal judgment.Episode Topics:Why We Are Replaying This Episode: Prices, Access, and UpdatesThe Insurance Landscape: Understanding Prior AuthorizationsMeet the Obesity Medicine SpecialistsDeconstructing the GLP-1 Muscle Loss NarrativeStrategies for Protecting Your MetabolismWhat the Scales Do Not Show About Insulin ResistanceNatural Satiety Triggers and Gut ReceptorsRecognizing Obesity as a Biological Chronic DiseaseAddressing Weight Stigma and External CommentarySubscribe to The Plus Sidez Podcast for science-backed episodes breaking down metabolic health, body recomposition, and the truth about weight loss.Search TagsGLP1 lies debunked, Ozempic myths, Mounjaro weight loss journey, Wegovy truth, Zepbound body recomposition, insulin sensitivity hacks, natural GLP1 boosters, treating obesity metabolic disease, plus sidez podcast, dr matea rentea, dr ali novitzki_________________________________________________________________________Join this channel to get access to perks:https://www.youtube.com/channel/UC0HUIGKl3BN4Vg6LYI-dkOA/join_________________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovySend us Fan Mail!Support the showKim Carlos, Executive Producer TikTokInstagram Kat Carter,  Producer TikTokInstagram 

SLC is officially one of America's "stickiest" downtowns — we break down the new Gensler study and what it means (plus where Denver landed). The flesh-eating screwworm just crossed into Texas for the first time in 60 years. Utah officials are watching closely. The Utah prison system is saving taxpayer dollars with a complete healthcare redesign — but it raises some interesting questions. We dive in with the Morality Police. In Health Class, a new study says Ozempic and Wegovy may slow biological aging by 9%.  Ethan and Alex put their friendship to the test after reading about the red flags that suggest a friendship isn't worth saving. Plus: a 17-year-old drowns at Bear Lake and trauma season is here. Why do Americans hate sharing bathrooms? Scammers are using AI images of a missing Utah cat to demand thousands, a couple is charged for hoarding hundreds of "street rats," and a man lost $30K because squirrels love plant-based car parts. Plus, Uber drops its wildest lost-and-found list ever (dentures, a Donny Osmond photo, 420 donuts).  AI Question of the Day: What's the best way to handle pet deaths with kids?   Stream KSL NewsRadio LIVE: kslnewsradio.com/listen Watch on YouTube: https://www.youtube.com/@KSLBrightside Facebook: https://www.facebook.com/KSLBrightside Instagram: https://www.instagram.com/KSL_Brightside TikTok: https://www.tiktok.com/@ksl.brightside

Amye is joined by Axel to discuss This is Poly S1:EP2 What Happens at The Strip ClubGET BONUS CONTENTUnlock ad-free episodes and exclusive bonus recaps by joining our community!Patreon: patreon.com/littlemissrecapWebsite: littlemissrecap.com/supportSUPPORT OUR SPONSORSFACTOR MEALS helps you save time in the kitchen with delicious, nutritious, chef-prepared cuisine. Meals come fully prepared and ready to eat in 2 minutes.Use our link and get 50% off your first box plus free shipping. Visit: www.factormeals.com/littlemiss50off and use code littlemiss50off.Hers now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy pill and the Wegovy pen. Visit forhers.com/LMR to get personalized, affordable care that gets you. OUR OTHER SHOWS & MERCHTrue Crime: Hear our latest documentary deep-dives on Murder She Watched at murdershewatchedpod.comShop Merch: Get your podcast gear at littlemissrecap.threadless.comCONNECT WITH USInstagram: @littlemissrecapFacebook Group: Little Miss Recap Podcast CommunityYouTube: Watch our recaps hereContact: Voicemail at littlemissrecap.com or email littlemissrecap@gmail.com Hosted on Acast. See acast.com/privacy for more information.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)What If the Lowest Dose Isn't Actually the Safest Dose?If you've spent any time in weight loss or wellness spaces online, you've probably come across the term microdosing — and chances are, it was framed as the smarter, gentler, more mindful way to use GLP-1 medications. But is that actually true? That's exactly what we're digging into today.In this episode, we cover:Is "Microdosing" GLP-1s Actually a Thing? — Where the term came from, why it took off, and whether it holds up clinically.The Right Dose Is the One That's Actually Working for You — What therapeutic dosing actually means and how to know if yours is doing its job.Weight Loss Is a Side Effect, Not Always the Goal — Why the scale isn't the only thing worth tracking — and what to measure instead.There Is No Prize for the Lowest Dose — The real cost of staying subtherapeutic and why "less is more" doesn't always apply here.There is no prize for taking the lowest dose. The goal isn't to stay as low as possible, and it isn't to push as high as possible either. The goal is to find the dose that actually works for you — for your body, your health conditions, and your specific outcomes. Check out the full episode and give it a listen — it's worth your time.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

One of the biggest questions people ask about GLP-1 medications is:“What happens if I stop taking it?”Whether you're taking Ozempic, Wegovy, Mounjaro, or Zepbound, you may have concerns about losing insurance coverage, reaching your goal weight, medication costs, long-term use, or the possibility of regaining weight in the future.In this episode, Registered Dietitian and GLP-1 expert Gianna breaks down what the research actually shows about stopping a GLP-1 medication, the factors that influence weight regain, and what you can start doing now to support long-term success.We're covering:What happens when you stop a GLP-1 medicationWhether weight regain is inevitableWhy hunger and food noise may change after discontinuationCommon myths about stopping Ozempic, Wegovy, Mounjaro, and ZepboundWhy willpower is not the solutionThe habits that support long-term weight maintenanceWhat to do if you lose access to your medicationHow to think about weight regain without shame or fearIf you've ever worried about what happens after a GLP-1, this episode will help you approach the conversation with more knowledge, less fear, and a realistic plan for the future.

A headline like “weight loss drugs may reduce breast cancer risk” grabs attention fast, but the real story lives in the fine print. We take you through a new Penn Medicine study that observed lower breast cancer rates among women with overweight or obesity who used GLP-1 medications, then we translate what that finding actually means in plain language. Observational data can reveal a signal worth studying, but it cannot prove the medication caused the outcome, and that distinction matters for your decisions and your expectations. We also zoom out to the bigger why: obesity is not just about body size. Fat tissue is biologically active, shaping chronic inflammation, estrogen exposure after menopause, insulin resistance, and even how well the immune system spots abnormal cells. Those pathways help explain why obesity is linked to many cancers, including postmenopausal breast cancer, and why researchers are curious whether effective obesity treatment could shift risk over time. Then we get practical. We review what stronger evidence from randomized controlled trials says so far: GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound do not appear to increase breast cancer risk in the available trial data, even though most trials were not designed to study cancer outcomes for many years. We also discuss why newer studies seem most suggestive for hormone receptor positive breast cancer, along with the leading theories: weight loss itself, improved metabolic health and insulin signaling, reduced inflammation, and the still-unclear possibility of direct GLP-1 effects in cancer biology. If you like evidence-based medicine with real-world context (and a little Philly-life banter), subscribe, share this episode with a friend, and leave a review so more people can find the show. What question do you want answered next about GLP-1s, obesity treatment, or cancer risk?ReferencesRisk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-Analysis. Ko A, Chang YC, Bahar F, et al. Annals of Internal Medicine. 2025;. doi:10.7326/ANNALS-25-02237.Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-Analysis. Piccoli GF, Mesquita LA, Stein C, et al. The Journal of Clinical Endocrinology and Metabolism. 2021;106(3):912-921. doi:10.1210/clinem/dgaa891.Glucagon-Like Peptide 1 Receptor Agonists and Cancer Risk: The Good, the Bad and the Unknown. Mannucci E, Dicembrini I. Nature Reviews. Clinical Oncology. 2026;23(6):459-470. doi:10.1038/s41571-026-01135-0.GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women. McDonald ES, Gillis LB, Gabriel P, et al. JCO Oncology Practice. 2026;:101200OP2600485. doi:10.1200/OP-26-00485.GLP-1 therapy and hormone receptor–positive breast cancer risk and survival: A real-world analysis.. Shah Z, Hundal J, Afridi S, et al. Journal of Clinical Oncology. 2026;44(Suppl 16):10548. doi:10.1200/JCO.2026.44.16_suppl.10548.Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer. Tatum KL, Dahman B, Stevenson A, et al. JAMA Network Open. 2026;9(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133.Association of Glucagon-Like Peptide-1 Receptor Agonists With Risk of Cancers-Evidence From a Drug Target Mendelian Randomization and Clinical Trials. Sun Y, Liu Y, Dian Y, et al. International Journal of Surgery (London, England). 2024;110(8):4688-4694. doi:10.1097/JS9.0000000000001514.GLP-1 receptor agonists and breast cancer risk in type 2 diabetes.. Guo Cheng and Amanda Ward. Journal of Clinical Oncology. 2025;43(Suppl 16):10557. doi:10.1200/JCO.2025.43.16_suppl.10557.Glucagon-Like Peptide-1 Analogues and Risk of Breast Cancer in Women With Type 2 Diabetes: Population Based Cohort Study Using the UK Clinical Practice Research Datalink. Hicks BM, Yin H, Yu OH, et al. BMJ (Clinical Research Ed.). 2016;355:i5340. doi:10.1136/bmj.i5340.GLP-1 Receptor Agonists and Cancer: Current Clinical Evidence and Translational Opportunities for Preclinical Research. Valencia-Rincón E, Rai R, Chandra V, Wellberg EA. The Journal of Clinical Investigation. 2025;135(21):e194743. doi:10.1172/JCI194743.Send us a (voice ) message with this link, we would love to hear from you. Standard message rates may apply.Support the showProduction and Content: Edward Delesky, MD, DABOM & Nicole Aruffo, RNArtwork Rebrand and Avatars:Vantage Design Works (Vanessa Jones) Website: https://www.vantagedesignworks.com/Instagram: https://www.instagram.com/vantagedesignworks?igsh=aHRuOW93dmxuOG9m&utm_source=qrOriginal Artwork Concept: Olivia Pawlowski

What happens to bariatric surgery when GLP-1 medications like Ozempic, Wegovy, and Zepbound change the entire weight loss landscape?In this episode, Dr. Matthew Weiner and registered dietitian Zoe unpack what they saw at the 2026 ASMBS annual conference - a meeting that felt very different from prior years. Surgical volumes are down, many bariatric surgeons are wrestling with what GLP-1s mean for their practices, and patients are left trying to figure out whether medication, nutrition, surgery, or some combination makes the most sense.Dr. Weiner explains why bariatric surgery still matters, but no longer belongs in the same place in the treatment sequence. For many patients, a GLP-1 trial should come first. For others, especially non-responders, patients with severe diabetes, or people losing mobility, surgery may be the safest and most effective next step.They also discuss why low-dose GLP-1s may be more sustainable than high-dose treatment, how to recognize a medication non-response, and why the best obesity care in 2026 combines nutrition, medication, surgery, and long-term support instead of forcing patients into one silo.

DC EKG with Joe GroganThe Economics of Ozempic and Other Weight Loss DrugsEpisode 136.5 (“Prescription Refill” – A replay from the archives)Original Air Date: May 2024In this episode, Joe Grogan welcomes Ben Ippolito, Senior Fellow in Economic Policy Studies at the American Enterprise Institute, to discuss the rapidly evolving economics of GLP-1 weight loss drugs like Ozempic and Wegovy.Ben explains the two main competitors in this market—Novo Nordisk's Ozempic and Wegovy versus Eli Lilly's Mounjaro and Zepbound. Revealing how insurance coverage decisions drive pharmaceutical marketing strategy.The conversation reveals a critical irrationality in Medicare policy: the statutory prohibition on covering weight loss drugs despite their profound clinical and quality-of-life benefits. Yet these same drugs are covered for diabetes and cardiovascular risk reduction.Ben explores the surprising economics of drug pricing through gross-to-net pricing—the massive gap between list prices and what insurers actually pay through rebates and discounts.The episode examines critical implications of the Inflation Reduction Act's price negotiation provisions. Once Medicare negotiates Ozempic's price, that same price applies to all products using the same active ingredient. This creates cascading market effects: competitors must match those prices to remain on formularies, new entrants face lower pricing power even if clinically superior, and pharmaceutical companies may abandon promising programs due to regulatory uncertainty.Ben argues Congress doesn't need to act immediately to expand Medicare coverage, but likely will within a few years.Joe and Ben discuss unintended consequences of government price regulation, including effects on innovation and drug development pipelines. They explore how price controls announced before elections affect pharmaceutical strategy and development timelines.Concluding with Ben's research on Medicare Advantage and why both Democrats and Republicans scrutinize this private alternative to traditional Medicare. With over 50 percent of seniors enrolled in Medicare Advantage plans, bipartisan interest in reform is reshaping healthcare policy conversations on Capitol Hill.Key TopicsGLP-1 drugs, Ozempic, Wegovy, Mounjaro, Zepbound, weight loss medications, obesity treatment, Medicare coverage, drug pricing, Inflation Reduction Act, pharmaceutical competition, rebates, gross-to-net pricing, health economics, cardiovascular benefits, diabetes treatment, Medicare Advantage, healthcare policy, innovation incentivesKey Timestamps00:00 Cold Open: "Turned Up to 11"00:24 Welcome to DC EKG00:46 Meet Ben Ippolito (AEI)03:48 The GLP-1 Landscape: Ozempic, Wegovy, and the Field05:04 One Drug, Two Names06:45 Medicare's Weight-Loss Coverage Ban07:21 Blockbusters and Big Effect Sizes09:32 Why Isn't Congress Acting?10:17 Why It Costs Less Than You Think12:34 The Coverage Irrationality14:05 Quality of Life as a Real Benefit15:17 Beyond Weight: Cravings and Addiction18:21 Devil's Advocate: Why Cover It At All?19:48 Gross-to-Net and the Rebate Problem22:41 Why Can't You Just Pay Cash?25:43 The IRA and the Ozempic Price Cut27:32 One Ingredient, One Price30:10 Unintended Consequences in Part D34:01 New Competitors and Killed Programs38:03 What's Next: Medicare Advantage42:04 Wrap-Up and CreditsAbout the Guest(As of May 2024) Ben Ippolito is a Senior Fellow in Economic Policy Studies at the American Enterprise Institute. He holds a PhD and Master's degree in Economics from the University of Wisconsin-Madison and a Bachelor's degree in Mathematics and Economics from Emory University. Ben examines drug pricing policy, Medicare Advantage, and healthcare innovation economics with regular engagement with Congress.Podcast: DC EKG with Joe GroganGuest: Ben IppolitoSponsor: Survivors for SolutionsProducer: Stay on Course StudiosExecutive Producer: John CZ Czwartacki, DC EKG Podcast

Det går forrygende for Novos nye fedmepille Wegovy. Salget har netop rundet en markant milepæl, og en stor del af årsagen tilskrives en bestemt ting, som Novo har været rigtigt gode til at omstille sig på. Hør, hvorfor Novo har haft så stor succes med lanceringen af deres fedmepille og hvor stærkt pillen står i forhold til konkurrents Eli Lillys ditto. Gæst: Anna Sofie Laue. Vært: Mads Ring. Foto: Novo/PR.See omnystudio.com/listener for privacy information.

GLP-1s like Ozempic and Wegovy are all over the news and TV ads lately. Are they really a safe way to lose weight? Racquel Williams talks with medical professionals from Penn Medicine's Center for Weight and Eating Disorders about the benefits and risks of GLP-1s, plus how social media impacts body image and how mental health is connected to food. Then, Philly Pride is bigger than ever this year! Shara Dae Howard hits up the kickoff event at Sofitel Philadelphia to find out what's going on all month - including a performance by Patti LaBelle - and how the LGBTQ+ community feels about the Pride festival moving from the Gayborhood to the Ben Franklin Parkway.

What is it like to take the Wegovy pill? Does it actually melt the weight off, or is it just expensive nausea in a bottle? Cooper breaks down the science, the stats, and the real user horror stories . Brutal honesty, side effect nightmares, and one very confused co-host. You don't want to miss this.#WegovySideEffects #IsWegovyWorthIt #WeightLossMedication #NauseaNation #LoseWeight #HealthPodcast #ComedyPodcast #RealTalk #PodcastHumor #BeforeAndAfter #BodyPositivity #FitnessMotivation

On today's show Kristian and Winston talk about Masters of the Universe, Star Wars, Jason Statham, The next $1b movie, Doomsday, Spider-Man, The Odyssey, update everyone on the Schomedown Vault and more!   #mastersoftheuniverse #doomsday #avengersdoomsday #starwars #spiderman #marvel #theodyssey  00:00 Show Begins & Opening Banter 05:42 He-Man vs Scary Movie 21:20 Liquid IV & Hims 24:48 Star Wars Reactions 30:52 Will The Odyssey Make $1Billion Dollars?  What will? 49:14 Statham Stole My Bike? 50:58 Schmoedown Vault Update 52:28 Q&A 2:13:34 Superchat War SPONSORS: LIQUID IV: Go to https://www.LIQUIDIV.com and get 20% off your first purchase with code KRISTIAN at checkout  RUGIET: Head to https://www.rugiet.com/KRISTIAN and get 15% off your ED treatment. HIMS:  Ready to reach your goals? Visit https://www.hims.com/KRISTIAN to get a personalized, affordable plan that gets you. - Based on advertised cash price for 30-day supply of medication only. Membership required, fee not included, and billed separately. Weight Loss by Hims is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A.S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit https://www.hims.com

Nutritionist Leyla Muedin discusses research showing simple strength tests—grip strength and a five-rep sit-to-stand chair test—predict longevity in older women. In a University at Buffalo study of over 5,000 women ages 63–99 followed for eight years, stronger grip and faster chair-stand times were linked to lower mortality; every additional 7 kg of grip strength corresponded to a 12% reduction in death risk, and faster chair-stands were also associated with improved survival, even after adjusting for activity, cardiovascular fitness, and inflammation. She emphasizes prioritizing muscle-strengthening alongside aerobic exercise and suggests accessible resistance options (weights, bodyweight moves, or household items) with professional guidance as needed. She then cites UK Biobank data linking long-term statin use to declines in grip strength and appendicular lean mass, urging discussion with physicians and added vigilance, especially for those also using GLP-1 drugs that may reduce protein intake and muscle mass.

GLP-1 medications like Ozempic and Wegovy are changing bodies fast. But what happens to your skin, face and overall appearance after dramatic weight loss? In this episode, Lauren sits down with New York Plastic & Reconstructive Surgeon Dr. David Kashan to talk about the growing rise in “Ozempic face,” loose skin, body contouring, facelifts, skin removal surgery and the very real aesthetic side effects many people aren't talking about. Dr. Kashan, who trained at the renowned Cleveland Clinic, shares what he's seeing firsthand in his practice during the GLP-1 boom. Together, they discuss who is most affected by rapid weight loss, the most common procedures patients are requesting now, how long patients should stop GLP-1 medications before surgery, and whether non-surgical treatments can help improve skin laxity, facial volume loss and overall skin quality before considering surgery. If you're a woman in midlife navigating weight loss, aging, confidence, skin changes or considering GLP-1 medications yourself, this conversation is packed with honest insight, practical advice, and expert perspective you'll definitely want to hear. Show Notes David L. Kashan MD, FACS, Plastic & Reconstructive Surgery (516) 515-9267 Website: davidkashanmd.com Instagram: @davidkashanmd  

If you're on a GLP-1 and nobody told you how to eat on it, this one's for you. We get into it in depth.Andrea Donsky, nutritionist, bestselling author of Nourishing Menopause, 7x published menopause researcher, menopause educator, and co-founder of wearemorphus.com, sits down with nutrition and fitness coach Natalie Bean, who is GLP-1 certified and has spent 31 years helping people change how they eat. If you're taking Ozempic, Mounjaro, or Wegovy, thinking about it, or you just want to take back control with food, Natalie walks through what actually protects your body. Spoiler: protein is not optional, and the scale is not the whole story.What you'll learn:Why a GLP-1 can cost you 25 to 40 percent of your weight as muscle, and how to push back with foodHow much protein women in perimenopause and menopause really need (and why it climbs on a GLP-1)Whether you'll gain the weight back when you stop, and what a maintenance dose actually doesThe GLP-1 side effects nobody warns you about, from dry mouth to constipation to brittle bonesWhy cardio is not the enemy, and where strength training and cortisol fit inChapters0:00 GLP-1 and muscle loss: the Mayo Clinic stat that stopped me0:48 Meet Natalie Bean and who GLP-1 meds are really for4:45 Food noise, sugar cravings, and insulin resistance after 409:45 Do you gain the weight back after stopping a GLP-1?14:10 How much protein you actually need on a GLP-119:40 GLP-1 side effects: dry mouth, digestion, bones, dehydration25:10 Fiber, constipation, and eating every 2 to 3 hours30:10 Why consistency beats variety when you start over35:10 Cortisol, cardio vs strength, and non-negotiable supplementsListen to this next:Tired of Fighting Food Cravings? Try This Instead: https://youtu.be/2PQxAbnll8sWork with Natalie: https://nutritionforeverinc.com/Send us Fan Mail ======Morphus: Menopause Reimagined

The grilling continues as Whitney tangles once again with her comedic shadow-self, Kevin Christy Tickets for The Big Baby Tour https://www.whitneycummings.com SHOP: https://whitneycummings.com/index.html#store Thank you to our sponsors! CHUBBIES #ad Your new wardrobe awaits! Get 20% OFF @chubbies with the code WHITNEY at https://www.chubbiesshorts.com/WHITNEY #chubbiespod iRestore #ad Unlock your best hair & skin with @iRestorelaser and HUGE savings on iRESTORE with code WHITNEY at https://irestore.com/WHITNEY! #irestorepod HERS #ad Ready to reach your goals? Visit https://www.forhers.com/whitney to get personalized, affordable care that gets you. Weight Loss by Hers is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit https://www.forhers.com. RUGGABLE #ad Refresh your home at https://www.ruggable.com. Get 10% off your first order, sitewide, with promo code WHITNEY at https://www.ruggable.com.

Tim Conway Jr Show Hour 4 (6.3) It’s election day hangover time! Los Angeles had a ridiculous ballot yesterday with races for mayor, governor, sheriff, council, and everything else. The mayor’s race turned into a wild three-way between Karen Bass, Nithya Raman, and Spencer Pratt — yes, that Spencer Pratt. Big surprise: Spencer actually surged into second place. Atta boy! In health news, new studies say GLP-1 drugs like Ozempic and Wegovy might cut breast cancer risk by up to 35%. That’s actually pretty wild. And if you’re going to the World Cup at SoFi Stadium, bring a lot of cash. Tickets are insane, parking is $300, and ticket scams are everywhere. Meanwhile, the cost of living is still crushing everybody. What a time to be alive. See omnystudio.com/listener for privacy information.

On today's Kristian Harloff show, Kristian and Kevin Smets talk about Tom Holland's comments that he urged Sony to make the new Spiderman in the style of how Christopher Nolan makes his movies. We get into Kevins games, we talk MMA, box office predictions, Mando and Grogu, He-Man and more. Join us! #starwars #motu #spiderman  SPONSORS: LIQUID IV: Go to https://www.LIQUIDIV.com and get 20% off your first purchase with code KRISTIAN at checkout  RUGIET: Head to https://www.rugiet.com/KRISTIAN and get 15% off your ED treatment. HIMS:  Ready to reach your goals? Visit https://www.hims.com/KRISTIAN to get a personalized, affordable plan that gets you. - Based on advertised cash price for 30-day supply of medication only. Membership required, fee not included, and billed separately. Weight Loss by Hims is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A.S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit https://www.hims.com

Losing weight on Ozempic, Wegovy, or Mounjaro but feeling bloated, constipated, and miserable? There's a reason, and a new Mayo Clinic study finally proves it.76% of patients on GLP-1s tested positive for SIBO. 91% had methane overgrowth. Dr. Kenneth Brown breaks down why these drugs turn your small intestine into a swamp, why your microbiome decides if the drug even works, and the exact protocol to fix it without quitting the medication.If you're on a GLP-1 or thinking about it, watch this first.

03 Jun 2026. Abu Dhabi is freezing all rent hikes until further notice. Tenants signing new leases will pay the same rent as the preceding contract, with residential, commercial and industrial rents all frozen. We get analysis on what that means for the market. The Wegovy weight loss pill is here, with the UAE only the second country in the world to greenlight it. The country is also set to become a hub for Novo Nordisk’s Wegovy production, serving up to 70 countries across the Gulf, Africa and Central Asia. We hear from Executive VP Emil Larsen. Plus, with UAE fuel prices up nearly 66% since February, it’s getting more expensive to transport goods. Could the cost of food go up? We find out with the CEO of Choithrams. And DXB saw a welcome revenue boost from Eid Al Adha travel. We find out what families planning summer travel can expect at the world’s busiest airport.See omnystudio.com/listener for privacy information.

MASTERS OF THE UNIVERSE reviews are finally here and the reactions are pouring in! Kristian Harloff breaks down the first Rotten Tomatoes scores and reviews for the highly anticipated He-Man movie from Amazon MGM Studios. Are critics embracing Nicholas Galitzine's He-Man and Jared Leto's Skeletor, or are there cracks in the Power of Grayskull? Plus, new details emerge about Jared Leto's performance as Skeletor as the Masters of the Universe director reveals whether the actor was actually on set for key scenes. What does this mean for the future of the franchise and the film's visual effects? Also on today's show, Tom Holland reveals that he'd love to make an R-rated Spider-Man appearance, sparking speculation about Spider-Man's future in the MCU and beyond. Could we eventually see a darker version of Peter Parker on screen? In other movie news, a Gene Wilder biopic is officially in development, bringing the legendary actor's incredible career back into the spotlight. Kristian discusses who could play the iconic star of Willy Wonka & the Chocolate Factory, Young Frankenstein, and Blazing Saddles. And finally, the long-awaited Barbarella remake is officially moving forward. What does this mean for the classic sci-fi property, and can a modern version capture the spirit of the original? #MastersoftheUniverse #HeMan #Skeletor #TomHolland #SpiderMan #GeneWilder #Barbarella #MovieNews #KristianHarloff #MCU #AmazonMGM #EntertainmentNews SPONSORS: LIQUID IV: Go to https://www.LIQUIDIV.com and get 20% off your first purchase with code KRISTIAN at checkout  RUGIET: Head to https://www.rugiet.com/KRISTIAN and get 15% off your ED treatment. HIMS:  Ready to reach your goals? Visit https://www.hims.com/KRISTIAN to get a personalized, affordable plan that gets you. - Based on advertised cash price for 30-day supply of medication only. Membership required, fee not included, and billed separately. Weight Loss by Hims is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A.S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit https://www.hims.com

It's in the News! The top diabetes stories and headlines happening now. Top stories this week include: Afrezza inhaled Insulin is Approved for Kids, CGM + Ketone Monitor gets European approval, Food Coloring & Diabetes Study, Device Recalls include Omnipod and Dexcom, Beta Bionics shares more about their patch pump, ADA conference info and more! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcripts: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. ADA starts this week – safe travels to those of you heading to New Orleans. We'll be covering remotely so please follow on social – make sure to Like the FB page or join the group. We've got a wrap up episode planned for this podcast as well as some indepth interviews with the newsmakers from the conference. I will see some of you next week in Chicago. We have a couple of seats left for our Club 1921 dinner on June 10th in Northbrook – this is a FREE dinner for HCPs and patient leaders – all about screening for T1D. More info on the website under the events tab. Okay.. our top story this week: XX Afrezza inhaled insulin is now approved for kids and teens. The FDA okayed MannKind's afrezza for children 6 and older with type 1 and type 2 diabetes. MannKind says its proprietary Technosphere drug delivery platform enables the rapid absorption of insulin into systemic circulation. This follows FDA approval earlier this year for an update that revises recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. MannKind also completed enrollment in February for a study evaluating the initiation of Afrezza therapy shortly after type 1 diabetes diagnosis in pediatric patients.   The company said it made Afrezza available for eligible patients for $35 or less per month. Desmond Schatz, professor of pediatrics at the University of Florida College of Medicine, said: "Mealtime insulin can be especially challenging for children because eating and snacking patterns, activity levels, and daily settings like school and sports often vary. With its rapid onset and dosing at the start of a meal, Afrezza may help clinicians better match insulin therapy to how children and families live day to day, while offering a needle-free mealtime option." Lots more to come on this – we're working on a bonus episode with one of the pediatric endos who worked on the clinical trials that led to this approval – hopefully have that out later this week. https://www.massdevice.com/mannkind-fda-approval-inhaled-insulin-children/ XX FDA has agreed to consider a new drug for the treatment of adults with type 1 and chronic kidney disease. Finerenone (fy-near-uh-known) is currently approved in the US for adults with CKD associated with type 2 diabetes and for adults with heart failure with left ventricular ejection fraction of 40% or greater. Chronic kidney disease (CKD) is present in over one-third of adults with diabetes, and because it's such a serious condition, interventions are needed to reduce its incidence and help people live a long and prosperous life. https://www.docwirenews.com/post/fda-grants-priority-review-to-finerenone-snda-for-type-1-diabetes-associated-ckd XX Abbot gets European approval for the world's first dual glucose‑ketone sensing technology for people with diabetes. They're calling this Libre Duo and Libre Duo 10 Day, and it's designed to continuously measure glucose and ketone levels every minute. Abbott plans to begin launching Libre Duo systems in select European countries later this year. Libre Duo delivers up to 15 days of wear and will be offered to adults ages 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people ages 2 and older. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes   XX Huge recall for Omnipod. Insulin says a manufacturing issue through ongoing product monitoring that could result in insulin under-delivery  with specific lots of its Omnipod 5, Dash and Eros pods. Insulet said the scope of this action reaches approximately 7 million pods. This issue is separate from the March recall that affected certain Omnipod 5 lots. According to the Acton, Massachusetts-based company, some of its affected pods may have a small tear in the tubing (cannula) just above the skin. This tear lands between the pod and the point where the cannula enters the body. If this occurs, insulin may leak outside of the device instead of being fully delivered into the body as intended. This may lead to under-delivery of the therapeutic.   Individuals using an affected pod may notice wetness on the skin or pod adhesive or detect the smell of insulin. However, some cases may prove difficult to detect and go unnoticed. Of the approximately 7 million pods included in the action, approximately 60% have been consumed or are expired. The pods affected by the correction represent approximately 8.5% of the 2025 global Omnipod pod prodcution. Insulet says it has sufficient supply to replace affected pods. It expects no disruption to product availability. The company said it has notified the FDA and all other relevant regulatory authorities of its action.   The full list of affected pod lots can be found here. https://www.massdevice.com/insulet-another-omnipod-5-recall-dash-eros/ XX Dexcom is warning that certain scrapped glucose sensors have been stolen and resold. Dexcom said it has not received any reports of severe adverse events associated with the stolen product. One lot of scrapped devices carries a risk of infection for sensors that are not properly sterilized, and another lot had an elevated internal testing failure rate, meaning users would have an increased risk of having no sensor readings available. Dexcom said the affected sensors were stolen during the destruction process and then sold by third parties. The company routinely scraps sensors that do not meet its standards. The sensors are sent to a third-party vendor for destruction and recycling.   Dexcom said it traced sales of the stolen devices to Pharmsource, which is not an authorized Dexcom distributor but supplies some independent pharmacies and U.S. durable medical equipment distributors. Because of this, pharmacies that purchase products from Pharmsource should review their inventory, Dexcom said.   People with sensors from the affected lots should not use those sensors and can call customer support to request replacements. Dexcom has set up a website to help users check if their devices are affected. https://www.medtechdive.com/news/dexcom-warns-of-scrapped-glucose-sensors-being-resold/821139/ XX XX   Beta Bionics plans to debut its first insulin patch pump by the end of the second quarter of 2027, subject to Food and Drug Administration clearance. The device, called Mint, would be compatible with Beta Bionics' interoperable automated glycemic controller, a software that allows for the pump to automatically adjust insulin delivery based on readings from a glucose sensor. Beta Bionics first unveiled the prototype for Mint last year at the American Diabetes Association's Scientific Sessions. The device is expected to have a similar size and wear time, at three days, to Insulet's patch pumps on the market. It would have a 200-unit insulin reservoir.   Mint differs by containing a mix of reusable and disposable components. Beta Bionics plans to make the device exclusively available in the pharmacy channel, building on its existing agreements for its current iLet insulin pump. Beta Bionics is one of several diabetes tech companies developing patch pumps to compete with market leader Insulet. Tandem Diabetes Care and Medtronic spinoff MiniMed have also announced planned patch pumps. Tandem said it plans to file a 510(k) submission this quarter for a tubeless version of its small, durable pump, and Medtronic plans to submit its patch pump to the FDA this fall.   https://www.medtechdive.com/news/beta-bionics-to-launch-its-first-insulin-patch-pump-to-compete-with-insulet/821091/ XX CVS puts Zepbound back on it's coverage list – with it's Caremark PBM. They also added Foundayo, Lilly's obesity pill. CVS had dropped Lilly's Zepound last summer but kept competitor Wegovy. It'll be back at Caremark October first. All three of the nation's largest pharmacy ⁠benefit managers ​now cover Lilly's full obesity medicine portfolio. https://www.reuters.com/legal/litigation/cvs-brings-back-coverage-lillys-obesity-drug-zepbound-2026-05-28/   More to come, including a new benefit from metformin for women, something new from Tidepool, big news for T1D in Austalia and more.. XX A new study suggests that higher long-term exposure to food colouring additives — including both synthetic and natural colourings commonly found in processed foods and beverages — may be associated with an increased risk of developing type 2 diabetes. Researchers analyzed data from more than 108,000 adults in the French NutriNet-Santé cohort between 2009 and 2023, following participants for a median of just over eight years. During that time, 1,131 participants developed type 2 diabetes. The study found that people with the highest intake of total food colouring additives had a 38% higher risk of developing type 2 diabetes compared with non- or low-consumers.   Several specific additives were linked to increased risk, including caramel colouring additives such as total caramel (E150 family), plain caramel (E150a), sulphite ammonia caramel (E150d), and beta-carotene (E160a). Additional associations were observed for curcumin (E100), anthocyanins (E163), paprika extract (E160c), lutein (E161b), and cochineal-derived colourings (E120). "Our findings revealed positive associations between widely consumed food colouring additives and type 2 diabetes incidence," the authors wrote, adding that further research is needed to better understand the mechanisms behind the findings and whether food colouring regulations should be reevaluated. https://www.medscape.com/viewarticle/use-common-food-colours-tied-high-type-2-diabetes-risk-2026a1000hes XX Big news for Australia – their Therapeutic Goods Administration (TGA) approves Tzield. Tzield is now approved in Australia to delay the onset of stage 3 (or clinical) T1D in people aged eight years and older with stage 2 T1D – the early, pre-symptomatic stage of the condition, where changes in blood glucose levels have begun but insulin therapy is not yet required. Breakthrough T1D Australia Chief Executive Officer, Sydney Yovic, said the approval represented a transformational moment for Australians affected by T1D. https://newshub.medianet.com.au/2026/05/landmark-approval-of-tzield-in-australia-ushers-in-a-new-era-of-delay-for-type-1-diabetes/155036/ XX https://www.theatlantic.com/health/2026/05/diabetes-pregnancy/687324/ XX A common diabetes drug may hold great potential to help with aging, even if scientists aren't exactly sure why. According to a study, the drug metformin doesn't just help patients to effectively manage their type 2 diabetes. it may also give older women a better chance of living to 90. Scientists in the US and Germany used data from a long-term US study of postmenopausal women.   Records for a total of 438 people were selected – half of whom took metformin to treat diabetes, and half of whom took a different diabetes drug, sulfonylurea.   While there are some caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group. The study used age 90 as the marker for 'exceptional' longevity. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study. RCTs could follow further down the line to dig deeper into these results, the researchers suggest. In the meantime, as the global population continues to skew older, studies continue to find ways to keep us healthier for longer and reduce damage to the body as we age. https://www.sciencealert.com/a-common-diabetes-drug-is-linked-with-exceptional-longevity-in-women XX The American Diabetes Association® (ADA) will host the 2026 Scientific Sessions from June 5-8 in New Orleans. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening an expected audience of over 12,000 leading physicians, scientists, researchers, and healthcare professionals from around the globe. The premier diabetes meeting, which is also offered virtually, will feature the latest scientific findings in diabetes and obesity, where leading experts and peers will share findings in research for prevention, care, and cures at the Ernest N. Morial Convention Center. Key themes will include: Advancing obesity and metabolic health: Prevention, early detection, and disease modification: Improving cardiometabolic outcomes: Transforming care through innovation and access: New research will highlight how technology, artificial intelligence, and implementation strategies are reshaping diabetes care—reducing treatment burden, expanding access, and enabling more person-centered care. Advancing beta cell replacement and cure strategies: Fostering innovation: On Saturday, June 6, from 4:30-6:00 p.m., the Innovation Challenge, which debuted in 2023, invites emerging companies to pitch novel ideas to improve the lives of people living with diabetes. A panel of judges, with input from a live audience, determines which contestants will earn a private audience with potential funders. XX Tidepool, the nonprofit leader advancing innovation in diabetes technology, announced that Tidepool+ Direct Connect is now available through the Epic Showroom. Built on SMART on FHIR, Direct Connect brings interactive diabetes device data directly into Epic workflows, helping clinicians use patient data during routine care. "Tidepool has always focused on making diabetes data more accessible and actionable," said Brandon Arbiter, CEO. "We're excited to empower clinicians using Epic with insightful, intuitive patient data that fits directly into their encounter workflow so they can use it to improve care in the moment it matters."   Tidepool+ Direct Connect supports scalable deployment across Epic-enabled health systems. This architecture enables faster, more intuitive rollouts, enhancing Tidepool's existing EHR integration capabilities.   Direct Connect is part of Tidepool's ongoing work to improve how clinicians can use timely and relevant diabetes device data during patient visits to help drive better health outcomes.   The feature is now available in the Connection Hub of the Epic Showroom.   https://www.businesswire.com/news/home/20260527780274/en/Tidepool-Launches-in-Epic-Showroom-to-Bring-Diabetes-Device-Data-into-the-Point-of-Care XX

Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel Skowronski, who suggested that obesity could become a solved disease within just a few generations of innovation.What does that mean for the millions of patients still fighting for access to GLP-1 medications like Zepbound, Mounjaro, and tirzepatide? And what is Lilly seeing in its pipeline that the rest of us can't?We dig into:Lilly's decision to stop disclosing its Phase 1 pipelineThe Camurus fluid crystal technology deal and what it means for long-acting GLP-1sEloralintide — Lilly's selective amylin agonist and potential dark horse in obesity medicineHow eloralintide compares to Novo Nordisk's cagrilintideWhy the future of obesity treatment is a toolbox, not a scoreboardThe access crisis: prior authorizations, insurance exclusions, Medicare, and Medicaid coverage gapsRetatrutide, quintuple agonists, and what's coming out of ADA 2026If you're on Zepbound, Wegovy, Ozempic, or any GLP-1 medication — or you're waiting for the next generation of obesity drugs — this episode is for you.

North Carolina has become a major player in the booming weight-loss drug industry, helping drive the next generation of medications like Ozempic and Wegovy. We look at how the state became a hub for these drugs, how they work and the risks that remain, plus the debate over coverage, costs and who gets access.

GLP-1 weight loss is about so much more than just the number on the scale.If you're taking Ozempic, Wegovy, Mounjaro, or Zepbound and feeling emotionally overwhelmed, anxious, conflicted, or even surprised by how much this journey is affecting your mindset—you are not alone.In this episode, Registered Dietitian and GLP-1 expert Gianna dives into the mental and emotional side of GLP-1 weight loss that almost nobody talks about.We're covering:How GLP-1 medications can change your relationship with foodWhat “food noise” is and why reduced food thoughts can feel emotionalWhy body image struggles don't automatically disappear with weight lossThe pressure of social media transformation cultureFear of weight regain and “what if this stops working?” thoughtsWhy needing a GLP-1 does not mean you failedIdentity shifts that can happen during major body changesHow to build a healthier mindset around sustainable weight lossWhether you're newly starting Ozempic, Wegovy, Mounjaro, or Zepbound—or deep into your GLP-1 journey—this episode is a reminder that your mental health matters too.Because sustainable health is not just about shrinking your body. It's about supporting your whole self.

It's Episode 18 of Season 24. Enter the dark waters of the Cape Fear River as we present tales about perilous pairs."Worms" by Nick Porisch (Story starts around 00:07:05)TRIGGER WARNING!Produced by Phil MichalskiCast: Evie - Sarah Ruth Thomas, James - Jeff Clement, Kid - Matthew Bradford, Driver - Graham Rowat"One in a Million" by D.H.Parish (Story starts around 00:31:20)Produced by Phil MichalskiCast: Narrator - Dan Zappulla, Courtney - Mary Murphy, Jeff - Atticus Jackson"I'm a state patrol officer. I know what really happens between mile markers 189 and 206." by Jamie Frances Janazian (Story starts around 00:52:30)Produced by Claudius MooreCast: Zac - Mike DelGaudio, Marta - Linsay Rousseau"Silo" by Erin Michelitsch (Story starts around 01:12:30)Produced by Jeff ClementCast: Narrator - Erin Lillis, Julie - Linsay Rousseau, David - Graham Rowat"The Skull on the Headland" by Simon Bleaken (Story starts around 01:28:35)TRIGGER WARNING!Produced by Jesse CornettCast: Narrator - David Ault, Carolyn - Ash Millman, Rebecca - Erika Sanderson, Stephen - Jake Benson, Lauren - Penny Scott-AndrewsThis episode is sponsored by:Storyworth - Create collaborative books to celebrate milestones, collect stories and photos from trips, gather recipes, and preserve all of lifeís memories. Head to storyworth.com/nosleep to save up to $20 and make memories that will last a lifetime.Boll & Branch - Discover your best sleep with bedding from Boll and Branch. Find the perfect balance of comfort, breathability, and craftsmanship. Get 20% off your first order, plus free shipping during the Memorial Day Sale at BollAndBranch.com/nosleep with code nosleep.Weight Loss by Hims - Ready to reach your weight loss goals? Weight Loss by Hims and WegovyÆ. Get a personalized, affordable plan that gets you. Go to Hims.com/nosleep.Click here to learn more about The NoSleep Podcast teamClick here to learn more about this episode's host: David AultCheck out our NEW MERCH!Click here to learn more about the Crimewave at Sea 2.0 Cruise!Click here to get your Crimewave at Sea discount code and bonus event!Click here to learn more about D.H.ParishClick here to learn more about Erin Michelitsch Executive Producer & Host: David CummingsMusical score composed by: Brandon Boone"The Skull on the Headland" illustration courtesy of Alia SynesthesiaThe NoSleep Podcast is Human-made for Human Minds. No generative AI is used in any aspect of work.Audio program ©2026 - Creative Reason Media - The copyrights for each story are held by the respective authors. No duplication or reproduction of this audio program is permitted without the written consent of Creative Reason Media. No part of this audio program may be used or reproduced in any manner for the purpose of training artificial intelligence technologies or systems. All rights reserved.

GLP-1 medications are changing the conversation around weight loss, metabolism, and women's health. But are we asking the right questions about long-term health?In this solo episode, Dr. Mindy Pelz breaks down the science behind GLP-1 drugs like Ozempic, Wegovy, and Mounjaro, including what they do well, where concerns are emerging, and how fasting mimics many of the same metabolic benefits naturally.Dr. Mindy explores: • The connection between GLP-1 drugs and muscle loss • Why women over 40 need to think differently about metabolism • New research linking GLP-1s to declining bone density • How fasting impacts glucagon, ketones, and fat burning • The importance of protein, refeeding, and resistance training • Why metabolic flexibility matters more than rapid weight loss • Natural ways to stimulate your body's own GLP-1 productionThis episode is not about fear or shame. It's about helping you understand your options so you can make informed decisions for your body, your hormones, and your long-term health.For more resources related to today's episode, visit the podcast episode page: https://www.drmindypelz.com/ep341Connect with Dr. Mindy:Join Reset AcademyWatch the episodes on YouTubeFollow Dr. Mindy on InstagramSubscribe to Dr. Mindy's newsletterDisclaimer: This podcast is intended for educational and informational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare professional before making changes to your diet, fasting routine, or lifestyle.

When Maziar Mike Doustdar took over as CEO of Novo Nordisk last year, the company had lost ground in the anti-obesity drug market. Doustdar spoke with Jessica Mendoza about his plans to turn the company around, the recent success of their Wegovy pill and what keeps him up at night. Further Listening: - Ozempic Is a Hit. So Why Is the Drugmaker's CEO Out? - Trillion Dollar Shot Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices